Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.

Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM.

Sci Transl Med. 2011 Jun 29;3(89):89ra57. doi: 10.1126/scitranslmed.3002156.

2.

Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy.

Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO.

Acta Neuropathol. 2011 Apr;121(4):431-43. doi: 10.1007/s00401-011-0801-7. Epub 2011 Jan 23.

PMID:
21259015
3.

Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.

Rolyan H, Feike AC, Upadhaya AR, Waha A, Van Dooren T, Haass C, Birkenmeier G, Pietrzik CU, Van Leuven F, Thal DR.

J Neural Transm (Vienna). 2011 May;118(5):699-712. doi: 10.1007/s00702-010-0572-7. Epub 2011 Jan 6.

PMID:
21210284
4.

Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ.

Science. 2010 Dec 24;330(6012):1774. doi: 10.1126/science.1197623. Epub 2010 Dec 9.

5.

Differential effects of the APOE genotype on brain function across the lifespan.

Filippini N, Ebmeier KP, MacIntosh BJ, Trachtenberg AJ, Frisoni GB, Wilcock GK, Beckmann CF, Smith SM, Matthews PM, Mackay CE.

Neuroimage. 2011 Jan 1;54(1):602-10. doi: 10.1016/j.neuroimage.2010.08.009. Epub 2010 Aug 10.

PMID:
20705142
6.

Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease.

Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kölsch H, Del Tredici K, Attems J, Ghebremedhin E.

Acta Neuropathol. 2010 Aug;120(2):169-83. doi: 10.1007/s00401-010-0707-9. Epub 2010 Jun 10.

PMID:
20535486
7.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators.

Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.

8.

Hypoperfusion and ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD brain perfusion SPECT.

Chung YA, O JH, Kim JY, Kim KJ, Ahn KJ.

J Nucl Med. 2009 Dec;50(12):1969-74. doi: 10.2967/jnumed.109.062315. Epub 2009 Nov 12.

9.

ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons.

Du J, Chang J, Guo S, Zhang Q, Wang Z.

Neurosci Lett. 2009 Oct 23;464(2):140-5. doi: 10.1016/j.neulet.2009.07.032. Epub 2009 Jul 16.

PMID:
19616072
10.

Reduced levels of human apoE4 protein in an animal model of cognitive impairment.

Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, Koger D, Paul S, Bales KR.

Neurobiol Aging. 2011 May;32(5):791-801. doi: 10.1016/j.neurobiolaging.2009.05.011. Epub 2009 Jul 4.

PMID:
19577821
11.

Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age.

Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ.

Ann Neurol. 2009 Jun;65(6):650-7. doi: 10.1002/ana.21696.

PMID:
19557866
12.

Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis.

Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE.

J Neurosci. 2009 Apr 1;29(13):4252-62. doi: 10.1523/JNEUROSCI.5572-08.2009.

13.

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.

Bell RD, Zlokovic BV.

Acta Neuropathol. 2009 Jul;118(1):103-13. doi: 10.1007/s00401-009-0522-3. Epub 2009 Mar 25. Review.

14.

Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism.

Zhao L, Lin S, Bales KR, Gelfanova V, Koger D, Delong C, Hale J, Liu F, Hunter JM, Paul SM.

J Neurosci. 2009 Mar 18;29(11):3603-12. doi: 10.1523/JNEUROSCI.5302-08.2009.

15.

Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein.

Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF.

PLoS One. 2009;4(2):e4627. doi: 10.1371/journal.pone.0004627. Epub 2009 Feb 27.

16.

Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy.

Hawkes CA, McLaurin J.

Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1261-6. doi: 10.1073/pnas.0805453106. Epub 2009 Jan 21.

17.

SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells.

Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV.

Nat Cell Biol. 2009 Feb;11(2):143-53. doi: 10.1038/ncb1819. Epub 2008 Dec 21.

18.

apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV.

J Clin Invest. 2008 Dec;118(12):4002-13. doi: 10.1172/JCI36663. Epub 2008 Nov 13.

19.

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA.

Brain. 2008 Dec;131(Pt 12):3299-310. doi: 10.1093/brain/awn261. Epub 2008 Oct 25.

PMID:
18953056
20.

Human apolipoprotein E4 targeted replacement mice show increased prevalence of intracerebral hemorrhage associated with vascular amyloid deposition.

Sullivan PM, Mace BE, Estrada JC, Schmechel DE, Alberts MJ.

J Stroke Cerebrovasc Dis. 2008 Sep;17(5):303-11. doi: 10.1016/j.jstrokecerebrovasdis.2008.03.011.

PMID:
18755411

Supplemental Content

Support Center